VERA News and Press, Vera Therapeutics Inc. From 01/31/23

Summary Vera Therapeutics has released an updated interim PP analysis on the phase 2b ORIGIN trial. The updated data excluded 14 patients who had some degree of a trial protocol violation, further enriching the data. The PP data was better than ITT data, where 36 weeks of data of th...

A higher dosage strength of Vera Therapeutics ( NASDAQ: VERA ) atacicept, under investigation for the kidney inflammation disorder IgA nephropathy, led to a significant reduction in proteinuria compared to placebo in a phase 2b study. Results showed that at 24 weeks, patients on the 1...

Vera continuing plans to rapidly advance atacicept into a pivotal Phase 3 trial in 1H 2023; full data to be presented at upcoming medical congresses Company plans to prioritize and focus current resources on the advancement of atacicept in IgA Nephropathy into a pivotal Phase 3 trial, ext...

BRISBANE, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced that it will host a virtual key opini...

Shares of the developmental-stage immunology company Vera Therapeutics (NASDAQ: VERA) gained a stately 49% this week, according to data provided by S&P Global Market Intelligence . Even so, the drugmaker's shares are down by a hefty 53% for the full month of January. What spar...

Summary Vera’s phase 2b ORIGIN data was underwhelming with lower than expected proteinuria reduction ~31% even at 9 months. We believe Atacicept’s commercial opportunity in IgAN is questionable due to the high degree of competition from KDNY, Otsuka, and Remegen. VERA ...

Summary 2023 should be a year of progress on kidney disease, with multiple catalysts lined up from multiple companies. Chinook Therapeutics, Inc. has the best risk-reward based on: i) valuation; ii) diversity of pipeline (ERA and anti-APRIL); and iii) clear catalyst in Q3 2023 (phase 3 ...

Wedbush downgraded Vera Therapeutics to neutral from outperform following the release of mid-term data for immunoglobulin A nephropathy (IgAN) candidate atacicept. The firm also cut its target price to $8 from $33 (~24% upside based on Wednesday's close). Vera ( NASDAQ: VERA ...

The Nasdaq Composite (NASDAQINDEX: ^IXIC) tried to bounce back on Wednesday morning, seeking to recover losses from the first trading day of 2023. As of shortly after the opening bell, the Nasdaq had moved up by more than half a percent. Individual stocks within the Nasdaq have seen h...

Vera Therapeutics ( NASDAQ: VERA ) is down 65% in after-hours trading Tuesday after releasing top-line data from a phase 2 trial of atacicept in patients with immunoglobulin A nephropathy (IgAN). Although the candidate met its primary endpoint, investors may have been looking for ...